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Breast cancer remains a major cause of death in women in the developed world. As Toll-like receptors (TLRs) are widely
expressed on tumor cells and play important roles in the initiation and progression of cancer, they may thus serve as important
targets and have an eﬀective perspective on breast cancer treatment. Expression of TLRs on breast cancer cells and mononuclear
inﬂammatory cells can promote inﬂammation and cell survival in the tumor microenvironment. Inﬂammation and cancer are
related. It is well known that persistent inﬂammatory conditions can induce cancer formation, due to production of cytokines and
chemokines, which play a crucial role in promoting angiogenesis, metastasis, and subversion of adaptive immunity. TLR signaling
in tumor cells can mediate tumor cell immune escape and tumor progression, and it is regarded as one of the mechanisms for
chronic inﬂammation in tumorigenesis and progression. This paper delineates the expression of various TLRs in promotion of
inﬂammation and development of mammary tumors. Understanding the mechanisms through which TLRs on breast cancer cells
and inﬂammatory cells regulate growth, survival, and metastatic progression can make them potential targets for breast cancer
therapy.
1.Introduction
Breast cancer is the most common cancer among American
women, except for skin cancers. The chance of developing
invasive breast cancer at some time in a woman’s life is a
little less than 12%. It is the second leading cause of cancer
death in women, exceeded only by lung cancer. The chance
that breast cancer will be responsible for a woman’s death is
about3%[1].Althoughclinicalsignsofdisseminateddisease
occur in fewer than 10% of women at the time of diagnosis,
the disease relapses in the form of metastasis within 5 years
of surgery in about half of apparently localized tumors. It
is diﬃcult to predict the occurrence of distant metastases
since breast cancer is a heterogeneous disease encompassing
complex pathologic entities [2]. Thus, there is a need for new
and eﬀective breast cancer therapies.
A dynamic interaction between tumors and the
immune system is essential for tumor survival, growth, and
metastasis [3]. Tumors are inﬁltrated with large number
of immune cells that constitute a major cell population
in the tumor microenvironment. Tumor cells depend on
their microenvironment to provide signals for growth, anti-
apoptosis, angiogenesis, and metastasis [4]. However, tumor
cells are also under the surveillance due to their recognition
b yi m m u n ec e l l sa sf o r e i g n .T h e r e f o r e ,t u m o r sh a v et o
overcome such immune surveillance to progress. Analysis of
the interactions between tumor cells and the host’s immune
systemhasledtotherealizationthattumorcellshavedevised
multiple strategies to evade immune attack. Development of
an invasive cancer, however, is not only a result of the genetic
changes in the tumor cell but also the result of genetic and
epigenetic changes within the host. Host cells, including
inﬂammatory cells, endothelial cells, and ﬁbroblasts,
are recruited and activated in the microenvironment of
transformed cells. The acute inﬂammatory response might
succeed in eliminating the malignant cells, but if not, a
chronic inﬂammatory process develops in conjunction with2 International Journal of Breast Cancer
thedyingtumorcells.Thesubsequentreciprocalinteractions
between these responding normal host cells and genetically
altered cells result in the development of an invasive
cancer. There is a constant interplay between the innate
a n da d a p t i v ei m m u n es y s t e m s ,w h i c hl e a d st oap r o t e c t i v e
immune response against pathogens and transformed
cells and contributes eﬀectively to discrimination between
self and nonself. Persistent protumor immune responses
(inﬂammation),nowgenerallyacceptedasinitiatingprimary
tumor development, are also being recognized as mediators
of cancer metastasis. Thus, novel anticancer therapeutic
strategies targeting molecular and/or cellular mechanisms
regulating these collaborative interactions may provide
eﬃcacious relief for metastatic disease [5].
Both infection and sterile tissue injury generate strong
immune responses. This paradox was ﬁrst resolved by
Matzinger in 1994, who proposed that our immune sys-
tem is designed to combat danger, rather than mediate
recognition of nonself over self [6]. Pathogen-associated
molecular patterns (PAMPs) and endogenous molecules
created upon tissue injury, since called damage-associated
molecular patterns (DAMPs), signal the threat of either
infection or injury to the organism, independently of
their nonself- or self-identity [7–10]. Damage-associated
molecular patterns (DAMPs) include endogenous intracel-
lular molecules released by activated or necrotic cells and
extracellular matrix (ECM) molecules that are upregulated
upon injury or degraded following tissue damage. Among
the cellular receptors that sense these danger signals, Toll-
like receptors (TLRs) represent a key molecular link between
tissue injury, infection, and inﬂammation. TLRs are critical
in bridging innate and adaptive immune responses and play
a signiﬁcant role in cancer immunosurveillance [5]. Innate
immune cells including natural killer (NK), natural killer T
(NKT),andγδTcellsplayacriticalroleinprotectingthehost
againstcancer[5].Macrophagesanddendriticcells(DCs),in
particular, function as major sensors of invading pathogens
and transformed cells via the TLRs. Adaptive immunity is
crucial to the elimination of pathogens and tumor cells in
the late phase of host defense responses and generates more
speciﬁc tumor immunity and immunological memory [11].
TLRs are known to regulate cancer immunity and tolerance
bycontrollingthesuppressivefunctionofregulatoryT(Treg)
cell and through innate immune responses mediated by
otherimmunecells[11–13].TLRsignaling,criticalforinnate
and adaptive immune responses, has been thought to be
restricted to immune cells [14]. However, many studies
suggest that tumor cells bear TLRs and that TLR signaling
promotes tumor growth and immune evasion [15–17]. TLR
activation by DAMPs may initiate positive feedback loops
where increasing tissue damage enhances proinﬂammatory
responses leading to chronic inﬂammation. As TLRs are
widely expressed on tumor cells and immune cells and play
important roles in the initiation and progression of cancer,
they may thus serve as an important target and have an
eﬀective perspective on breast cancer treatment.
Currently, 13 mammalian-TLR analogs have been iden-
t i ﬁ e d .T L R s1 ,2 ,4 ,5 ,a n d6a r ee x p r e s s e do nt h ec e l l
s u r f a c e ;T L R s3 ,7 ,8 ,a n d9a r ef o u n da l m o s te x c l u s i v e l y
within endosomes. Diﬀerent TLRs exhibit speciﬁcity for
pathogen-derived ligands; TLRs 2, 3, 4, 5, 7, and 9 recognize
bacterial lipoproteins, double-stranded RNA/poly (I:C),
lipopolysaccharides (LPS), ﬂagellin, single-stranded RNA,
and CpG-containing DNA, respectively [18–23]. The ligands
for TLRs 10, 12, and 13 remain unidentiﬁed. TLR10 is
e x p r e s s e di nh u m a n sb u tn o ti nm i c e ,T L R 8i sn o tf u n c t i o n a l
in mice and TLRs 11, 12, and 13 are expressed in mice but
not in humans.
There are several studies which suggest that DAMP-
mediated inﬂammation plays a vital role. Necrotic cells were
found to induce proinﬂammatory and tissue repair gene
synthesis and cause DC maturation in a TLR2-dependent
manner, as a result of the release of their intracellular
contents. Other intracellular molecules such as heat shock
proteins including HSP70, Gp96, HSP22, and HSP72 and
high-mobility group box-1 protein (HMGB1) as well as
ECM molecules such as biglycan, tenascin-C, versican, and
fragments of ECM molecules including oligosaccharides of
hyaluronic acid (HA) and heparan sulfate (HS) have been
shown to activate TLRs. TLR1, along with TLR2, was found
to be important for the activation of professional antigen-
presenting cells by β-defensin-3, a host-derived antimicro-
bial peptide. Self-nucleic acids have also been described as
endogenous danger signals, namely, mRNA recognized by
TLR3, single-stranded RNA (ssRNA) sensed by TLR7 and 8,
and IgG-chromatin complexes recognized by TLR9. TLR2,
4, 7, and 8 were shown to be activated by antiphospholipid
antibodies (APL) isolated from patients with APL syndrome
[24].
The signaling pathways utilized by various TLRs diﬀer,
which results in varied cellular responses. For example,
TLR3, the receptor for double-stranded RNA couples to
the adaptor protein TRIF. In contrast, other TLRs couple
to the adapter myeloid diﬀerentiation primary response
gene 88 (MyD88) [25, 26]. The MyD88-adapter protein
recruits IRAKs and TRAF6. The TRAF6 in turn activates
TAK1 that phosphorylates and activates the IKK complex
resulting in the release and translocation of NF-κB to the
nucleus. TAK1 also activates stress-activated protein kinase
(SAPK) pathways and activates c-Jun-NH2-kinases (JNK)
and p38. The MyD88-coupled TLRs induce the synthesis of
cytokines such as TNF-α, IL-6, and IL-1, key mediators of
the inﬂammatory response [27, 28]. TLR4, the receptor for
LPS, is unique in that it activates both MyD88-dependent
and TRIF-dependent pathways [28].
2. Inﬂammation andCancerMetastasis
The link between inﬂammation and cancer is well docu-
mented [29, 30]. Several inﬂammatory diseases, including
inﬂammatory bowel disease, increase the risk of cancer.
Conversely, in tumors that are epidemiologically unrelated
to overt inﬂammatory conditions (such as breast cancer),
the activation of oncogenes can trigger the production of
inﬂammatory molecules and the recruitment of inﬂamma-
tory cells. In the tumor microenvironment, inﬂammatory
cells and molecules inﬂuence almost every aspect of cancerInternational Journal of Breast Cancer 3
progress, including the metastatic ability of tumor cells
[29]. There is biological heterogeneity among tumors with
regard to cellular inﬁltrates, identifying subsets of mononu-
clear inﬂammatory cells both at the tumor centre and at
the invasive front, which seem to be associated with the
occurrence of distant metastasis. Intratumour leucocytes
from peripheral blood penetrate the tumor architecture after
their phenotypic modiﬁcation, from the invasive front to
the tumor centre. This seems to be a dynamic process in
which inﬂammatory cells and immunomodulatory media-
tors present in the tumor microenvironment polarize the
host immune response towards speciﬁc phenotypes impact-
ing on tumor progression [31]. Previously, there were six
recognizedhallmarksofcancer,namely,unlimitedreplicative
potential, self-suﬃciency in growth signals, insensitivity to
growth inhibitors, evasion of programmed cell death, ability
to develop blood vessels, and tissue invasion and metastasis
[4]. Cancer-related inﬂammation has now emerged as the
seventh hallmark of cancer. A group of cytokine proteins,
including IL-1, IL-6, TNF-α, and RANKL, activate inﬂam-
mation and are known to augment tumor cells’ ability to
metastasize by aﬀecting several steps in the cells’ dissem-
ination and implantation at secondary sites [29, 32, 33].
Inﬂammatorycytokinesliedownstreamofthe“master”gene
transcription factor NF-κB, for promoting inﬂammation
which is itself activated by them [29]. There is strong
evidence that the tumor microenvironment is inﬂammatory
and that activation of the innate immune system plays a
role in the progression of cancer [34, 35]. A major source
of inﬂammatory cytokines in the tumor microenvironment,
are specialized white blood cells called macrophages. Tumor-
associated macrophages assist the malignant behaviour of
tumor cells, not only by producing cytokines, but also by
secretinggrowthfactorsandmatrix-degradingenzymes[36–
38]. It has long been suggested that there may be common
pathways of inﬂammation shared by responses to infection
and to malignancy. Recent evidence indicates that TLRs on
macrophages may be critical elements in these common
pathways. MyD88 has been reported to activate not only AP-
1a n dN F - κB subunit p65 and p50, but also c-Rel, C/EBPβ,
and C/EBPδ. In case of LPS signaling through TLR4, where
NF-κBandAP-1activitiesarerelativelypreservedinMyD88-
deﬁcient macrophages, the speciﬁc defect in c-Rel and the
profound defect in C/EBPβ/δ activation likely accounts for
the reduction of IL-12 p40, IL-6, and TNFα. The absence
of both C/EBPβ/δ speciﬁcally in TLR signaling impairs key
proinﬂammatory cytokines without aﬀecting other NF-κB-
dependent genes such as IκBα [39].
3.Toll-LikeReceptorsinInﬂammation-Induced
Breast Cancer
Toll-like receptors are expressed on cells of the immune
system but there is growing evidence that TLRs are also
expressed on tumor cells, where they may inﬂuence tumor
growth and host immune responses [15]. Activation of TLRs
expressed on tumor cells may have profound consequences
for tumor growth by factors released after TLR activation.
Tumor immune evasion may be facilitated by inhibitory
cytokines,inﬂammatoryfactors,proteinases,andothersmall
molecules such as nitric oxide [40]. Recent evidence suggests
that TLRs also contribute to tumor-cell resistance to apop-
tosis and increased invasiveness. The human breast cancer
cell line MDA-MB-231 was found to express TLR1-TLR10
at both the mRNA and protein levels. TLR4 was found to be
the highest expressed TLR in MDA-MB-231. Knockdown of
TLR4geneinMDA-MB-231resultedinadramaticreduction
of breast cancer cell viability and inhibition of IL-6 and IL-8
cytokines compared with vector control [41]. Another study
highlights the role of TLR9 in highly invasive MDA-MB-
231 breast cancer cell line which when activated promotes
MDA-MB-231 cell invasion by increasing the activity of
matrix metalloproteinase 13 (MMP13), but not MMP8 [42].
Samples of mammary carcinomas with recurrence have also
exhibited a signiﬁcant increase in the mRNA levels of TLR3,
TLR4, and TLR9. A signiﬁcant percentage of tumors also
showed TLR4 expression by mononuclear inﬂammatory
cells (21.6%) and TLR9 expression by ﬁbroblast-like cells
(57.5%). Tumors with high TLR3 expression by tumor cell
orwithhighTLR4expressionbymononuclearinﬂammatory
cells (MICs), but not TLR9 high ﬁbroblast like cells were
signiﬁcantly associated with higher probability of metastasis
[2]. This study highlights the importance of the tumor
stromal cells in tumor behavior, and how TLR-induced
inﬂammation on inﬂammatory cells drives metastatic cas-
cade.
Synthetic TLR9-ligands (CpG-sequence containing
oligonucleotides) stimulated TLR9 expressed on cancer cells
as well as various normal cells, including mesenchymal stem
cells and stimulated their invasion in vitro. This invasion
was mediated via downregulation of tissue inhibitor of
matrix metalloproteinase-3 (TIMP-3) and through matrix
metalloproteinase-13 (MMP-13) activation. Expression of
TLR9 isoforms A and B have been detected in clinical breast
cancer specimens. Expression of TLR9 and its invasive eﬀects
on breast cancer cells has been found to be regulated by
estrogen receptor-α (ERα) and sex steroid hormones. TLR9
expression was also found to be aﬀected by commonly used
hormonal cancer therapy bicalutamide [43].
Activation of TLR signaling on tumor cells by their
ligands can also trigger apoptosis and may have therapeutic
eﬀects. For example, in a randomized clinical trial for
the eﬃcacy of poly (A:U) dsRNA, therapeutic eﬀect was
mediated through TLR3 expressed on tumor cells, and
could therefore represent an eﬀective targeted treatment in
patients with TLR3-positive cancers. The predictive value
of TLR3 expression by tumor cells for the eﬃcacy of
Poly (A:U) dsRNA was determined in 194 breast cancer
patients enrolled in a randomized clinical trial. However,
conventional chemotherapy or in vivo injection of poly
(A:U), alone or in combination, failed to reduce tumor
growth unless an immune-chemotherapeutic regimen of
vaccination against tumor antigens was included [44].
Recently, TLR5 has been found to be highly expressed in
breast carcinomas and activation of TLR5-signaling pathway
was found to be overly responsive in breast cancer cells by
inhibiting cell proliferation and an anchorage-independent4 International Journal of Breast Cancer
growth. In addition, the secretion of soluble factors induced
by ﬂagellin, was found to the growth-inhibition of breast
cancer cells in an autocrine fashion. This inhibitory activity
was further conﬁrmed in vivo using mouse xenografts
models of human breast cancer cells [45]. Sites of chronic
inﬂammation are often associated with the establishment
and growth of various malignancies including breast can-
cer. Enhanced neutrophilic and granulocytic inﬁltration in
lungs and bone of the proarthritic and arthritic mice and
subsequent increase in circulating levels of proinﬂammatory
cytokines,suchasmacrophagecolonystimulatingfactor(M-
CSF), interleukin-17 (IL-17), interleukin-6 (IL-6), vascular
endothelial growth factor (VEGF), and tumor necrosis
factor-alpha (TNF-alpha) were found to contribute to the
increased metastasis. Breast cancer-associated secondary
metastasis was found to be signiﬁcantly increased in pro-
arthritic and arthritic conditions. Breast cancer metastasis
was found to be signiﬁcantly reduced by blocking the IL-17
and COX-2 pathway [46]. Inﬂammatory TLR signaling has
also been shown to promote the attraction and generation
of Th17 cells induced by tumor cells and tumor-derived
ﬁbroblasts. Enhanced migration of Th17 cells to tumor sites
was reported to be due to the expression of chemokines and
tumor-derived ﬁbroblasts [47].
Therapeutic development targeting TLRs is at early
clinical stages. There are currently approximately twenty
drugs in preclinical development, with a further dozen or
so in clinical trials [48]. There are clearly many options for
the targeting of TLRs, because the key function of TLRs
is to induce cytokines, which are well validated in these
diseases and are successfully being targeted in the clinic.
TLRs occur early in pathways and so inhibiting them might
be more potent than inhibiting their downstream cytokine
targets. Diﬀerent approaches are being taken to target TLRs.
Neutralizing antibodies to TLRs are a feasible option, but
only for those on the cell surface, such as TLR2, TLR4,
and TLR5. Small-molecule antagonists (e.g., eritoran against
TLR4 or ODN-based inhibitors of TLR7) might be a better
prospect, but it is hard to predict their oﬀ-target eﬀects
and eﬃcacy. Because there are kinases on the signaling
pathways, these might also be sensitive to inhibition. One
major concern here, however, is that such inhibitors might
block multiple TLRs and therefore give rise to unwanted
immunosuppression. Monotherapies against a speciﬁc TLR
might not have this problem. Studies on knockout mouse
indicate that there is less redundancy in TLRs in relation to
inﬂammation. TLR-based adjuvants also have the potential
to yield new agents. Imiquimod is already approved for
its antiviral eﬀects, whereas MPL is approved as a vaccine
adjuvant. In terms of antagonism, eﬀects of TLR inhibitor,
eritoran have been found to be signiﬁcant but somewhat
marginal [49].
To further develop more eﬀective TLR therapeutic tar-
geting strategy, there are a few more tasks: further iden-
tifying and determining the pathogenesis of challenging
medical conditions like cancer; analysis of genetic sequence,
molecular structure, epigenetic observations, and functional
activities on both animal model and human clinical studies;
design of clinical study based on study indication, dosing
regimens, drug delivery route or format consideration,
and pharmacokinetics; timely and objective assessment of
adverse events with details. Targeting TLRs will therefore in
all likelihood prevent the induction of many immune and
inﬂammatoryproteins.ThewidetissuedistributionofTLRs,
however, may make it diﬃcult to determine whether an
agonistoranantagonistwillbemosteﬀectivetherapeutically.
4. Conclusions
Metastasis is regulated not only by intrinsic genetic changes
in malignant cells, but also by the microenvironment.
Several studies have demonstrated that sites of chronic
inﬂammation are often associated with the establishment
and growth of various malignancies. Toll-like receptors
(TLRs) have emerged as sensors that can detect a variety of
invadingpathogensandmalignantcells.Sincetheirdiscovery
ad e c a d ea g o ,T L R sh a v eb e e ns h o w nt ob ec r i t i c a lf o r
eﬃcient innate and adaptive immunity and the framework
of TLR-mediated signaling pathway has been explained.
However, TLR activation may be a two-edged sword, with
both antitumor and pro-tumor consequences. The general
expression of functionally active TLRs by tumor cells and
inﬂammatory cells in the stroma by putative endogenous
ligands suggests that TLR signaling may be continually
activated and may contribute to tumor progression and
metastasis. Understanding TLR function in tumor biology
may lead to discovery of new therapeutic targets in cancer
therapy.
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